Table 2.
Demographics of patients for whom we have data on QoL at T0.
| Patients Aged 4–17 Years Whose Parents Reported on QoL at T0 (n = 109) | Patients Aged 12–17 Years Who Self-Reported on QoL at T0 (n = 23) | |
|---|---|---|
| Age, years | ||
| Mean (SD) | 11.3 (4.2) | 14.8 (1.9) |
| Median (IQR) | 12 (8, 15) | 15 (13, 17) |
| Range | 4–17 | 12–17 |
| Gender, n (%) | ||
| Female | 49 (45%) | 14 (61%) |
| Male | 60 (55%) | 9 (39%) |
| Age of patient at time of diagnosis, years | ||
| Mean (SD) | 10.0 (4.5) | 13.0 (2.8) |
| Median (IQR) | 10 (6, 14) | 13.5 (11, 15.25) |
| Range | 0–17 | 7–17 |
| Diagnosis, n (%) | ||
| Central Nervous System | 42 (39%) | 5 (22%) |
| Sarcoma | 34 (31%) | 12 (52%) |
| Leukemia/Lymphoma | 14 (13%) | 4 (17%) |
| Neuroblastoma | 9 (8%) | 0 (0%) |
| Other | 10 (9%) | 2 (9%) |
| Number of relapses for patient prior to PRISM consent, n (%) | ||
| 0 | 46 (42%) | 11 (48%) |
| 1 | 47 (43%) | 10 (44%) |
| ≥2 | 16 (15%) | 2 (9%) |
| Received cancer treatment while awaiting testing results | ||
| Yes | 87 (79.8%) | 20 (87%) |
| No | 22 (20.2%) | 3 (13%) |
| Time (days) from initial cancer diagnosis * to PRISM enrolment | ||
| Median (IQR) | 418.5 (11.5, 818) | 359 (83, 699) |
| Range | 0–5586 | 1–4023 |
| Time (days) from cancer event ** resulting in patient being eligible for PRISM and enrolment | ||
| Median (IQR) | 6 (1, 16.5) | 7 (1, 49) |
| Range | 0–834 | 0–155 |
* Some participants have been diagnosed with more than one type of cancer in their lifetime; ** Initial diagnosis, relapse or disease progression; SD = standard deviation; n = number; QoL = Quality of Life.